Fig. 9: Antitumoral effects of gilteritinib in EC PDX models.
From: Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors
Gilteritinib (10 mg/kg and 50 mg/kg) was administered orally once a day for 3–4 weeks. Antitumoral effects of gilteritinib on tumor growth in EC241 (A–D) and EC291 (E–H) PDX models. I, J IHC staining of Ki-67 in paraffin-embedded tumor tissue samples from the EC241 and EC291 PDX models. Images were captured at 400× magnification. Scale bars: 20 µm. Data represent the mean ± standard error of the mean (SEM) of at least three independent experiments; the statistical significance was assessed by unpaired t-test (ns Not significant; *p < 0.05; **p < 0.01; ***p < 0.001).
